Protein phosphatase 1 inactivates Mps1 to ensure efficient spindle assembly checkpoint silencing

  1. Margarida Moura
  2. Mariana Osswald
  3. Nelson Leça
  4. João Barbosa
  5. António J Pereira
  6. Helder Maiato
  7. Claudio E Sunkel  Is a corresponding author
  8. Carlos Conde  Is a corresponding author
  1. i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal

Abstract

Faithfull genome partitioning during cell division relies on the Spindle Assembly Checkpoint (SAC), a conserved signaling pathway that delays anaphase onset until all chromosomes are attached to spindle microtubules. Mps1 kinase is an upstream SAC regulator that promotes the assembly of an anaphase inhibitor through a sequential multi-target phosphorylation cascade. Thus, the SAC is highly responsive to Mps1, whose activity peaks in early mitosis as a result of its T-loop autophosphorylation. However, the mechanism controlling Mps1 inactivation once kinetochores attach to microtubules and the SAC is satisfied remains unknown. Here we show in vitro and in Drosophila that Protein Phosphatase 1 (PP1) inactivates Mps1 by dephosphorylating its T-loop. PP1-mediated dephosphorylation of Mps1 occurs at kinetochores and in the cytosol, and inactivation of both pools of Mps1 during metaphase is essential to ensure prompt and efficient SAC silencing. Overall, our findings uncover a mechanism of SAC inactivation required for timely mitotic exit.

Article and author information

Author details

  1. Margarida Moura

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  2. Mariana Osswald

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  3. Nelson Leça

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  4. João Barbosa

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  5. António J Pereira

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  6. Helder Maiato

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  7. Claudio E Sunkel

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    For correspondence
    cesunkel@ibmc.up.pt
    Competing interests
    The authors declare that no competing interests exist.
  8. Carlos Conde

    i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    For correspondence
    cconde@ibmc.up.pt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4177-8519

Funding

FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 (Norte-01-0145-FEDER-000029)

  • Margarida Moura
  • Claudio E Sunkel
  • Carlos Conde

Fundação para a Ciência e a Tecnologia (PTDC7BEX-BCM/1921/2014-PR041602)

  • Claudio E Sunkel

Fundação para a Ciência e a Tecnologia (PEst-C/SAU/LA0002/2013-Incentivo2014-BGCT)

  • Claudio E Sunkel

Fundação para a Ciência e a Tecnologia (FCT Investigator grant IF/01755/2014)

  • Carlos Conde

Fundação para a Ciência e a Tecnologia (GABBA PhD Program grant PD/BD/105746/2014)

  • Mariana Osswald

Fundação para a Ciência e a Tecnologia (FCT PhD grant SFRH/BD/87871/2012)

  • João Barbosa

European Research Council (PRECISE)

  • Helder Maiato

European Research Council (CODECHECK)

  • Helder Maiato

FLAD Life Science

  • Helder Maiato

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Moura et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,522
    views
  • 733
    downloads
  • 53
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Margarida Moura
  2. Mariana Osswald
  3. Nelson Leça
  4. João Barbosa
  5. António J Pereira
  6. Helder Maiato
  7. Claudio E Sunkel
  8. Carlos Conde
(2017)
Protein phosphatase 1 inactivates Mps1 to ensure efficient spindle assembly checkpoint silencing
eLife 6:e25366.
https://doi.org/10.7554/eLife.25366

Share this article

https://doi.org/10.7554/eLife.25366

Further reading

    1. Cell Biology
    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology
    2. Developmental Biology
    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.